Sees FY24 operating expenses $355M-$375M, which includes an estimated $43M in non-cash stock compensation expense. The Company believes that it has sufficient cash runway to fund its research, clinical development and commercial operations through 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNDX:
- Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- SNDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Syndax downgraded to Sector Perform from Outperform at Scotiabank
- Syndax says sufficient cash runway to fund operations through 2026
